Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

86.42USD
18 Jan 2018
Change (% chg)

$-0.46 (-0.53%)
Prev Close
$86.88
Open
$86.31
Day's High
$86.70
Day's Low
$86.22
Volume
1,465,190
Avg. Vol
1,515,946
52-wk High
$87.29
52-wk Low
$69.53

Latest Key Developments (Source: Significant Developments)

Novartis says data reinforces ‍Cosentyx effectiveness
Tuesday, 16 Jan 2018 01:15am EST 

Jan 16 (Reuters) - Novartis AG ::NOVARTIS NEW DATA REINFORCES SUPERIORITY OF COSENTYX® VERSUS STELARA®* IN ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS.‍CLARITY STUDY SHOW COSENTYX(®) (SECUKINUMAB) WAS SIGNIFICANTLY MORE EFFECTIVE THAN STELARA(®*) (USTEKINUMAB) IN DELIVERING CLEAR AND ALMOST CLEAR SKIN AT 12 WEEKS AND AT 16 WEEKS​.‍COSENTYX CONTINUED TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE​.  Full Article

FDA accepts Novartis submission of biosimilar version of Humira
Tuesday, 16 Jan 2018 01:00am EST 

Jan 16 (Reuters) - Novartis AG ::SANDOZ REGULATORY SUBMISSION FOR PROPOSED BIOSIMILAR ADALIMUMAB ACCEPTED BY FDA.US FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTED ITS BIOLOGICS LICENSE APPLICATION (BLA), SUBMITTED UNDER THE 351 (K) PATHWAY, FOR PROPOSED BIOSIMILAR ADALIMUMAB TO THE REFERENCE MEDICINE, HUMIRA.‍DATA PACKAGE PROVIDED IS EXPECTED TO DEMONSTRATE THAT SANDOZ PROPOSED BIOSIMILAR ADALIMUMAB MATCHES REFERENCE BIOLOGIC MEDICINE IN TERMS OF SAFETY, EFFICACY AND QUALITY​.  Full Article

Novartis poaches Pfizer oncology head Elizabeth Barrett
Thursday, 11 Jan 2018 01:00am EST 

Jan 11 (Reuters) - Novartis says::Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc. <<>>, has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018.Barrett succeeds Bruno Strigini who decided to retire from Novartis for personal reasons.  Full Article

Sandoz Canada Says Ontario Has Added Erelzi To Its Public Drug Plan
Tuesday, 9 Jan 2018 07:30am EST 

Jan 9 (Reuters) - Novartis Ag ::SANDOZ CANADA SAYS ONTARIO HAS ADDED ERELZI(TM) (ETANERCEPT) TO ITS PUBLIC DRUG PLAN FOR TREATMENT OF MULTIPLE INFLAMMATORY DISEASES​.  Full Article

Luye Pharma Group‍ Announces Update on Patent Litigation Regarding Rivastigmine 1 Day Patch
Wednesday, 27 Dec 2017 11:01pm EST 

Dec 28 (Reuters) - Luye Pharma Group Ltd <2186.HK>::COURT OF APPEAL FOR DISTRICT OF MUNICH, GERMANY DISMISSES APPEAL FROM NOVARTIS AG AS CLAIMANT IN PATENT INFRINGEMENT LAWSUIT.‍PATENT INFRINGEMENT LAWSUIT ON GROUP'S RIVASTIGMINE 1 DAY PATCH​.‍NOVARTIS AG HAS REIMBURSED GROUP OF RELEVANT LEGAL EXPENSES ​.  Full Article

FDA Updates Label Of Tasigna To Reflect That Certain Patients With Type Of Leukemia May Be Eligible To Stop Treatment After Sustained Response
Friday, 22 Dec 2017 02:46pm EST 

Dec 22 (Reuters) - U.S. FDA::FDA UPDATES LABEL OF NOVARTIS' TASIGNA TO REFLECT THAT CERTAIN PATIENTS WITH TYPE OF LEUKEMIA MAY BE ELIGIBLE TO STOP TREATMENT AFTER SUSTAINED RESPONSE.FDA SAYS UPDATED PRODUCT LABEL FOR CANCER DRUG TASIGNA TO INCLUDE INFORMATION FOR PROVIDERS ABOUT HOW TO DISCONTINUE THE DRUG IN CERTAIN PATIENTS.FDA - FDA GRANTED THE APPROVAL OF THE TASIGNA LABEL CHANGES TO NOVARTIS PHARMACEUTICALS CORPORATION.  Full Article

Novartis Multiple Sclerosis Therapy Fingolimod Granted FDA Breakthrough Therapy Designation For Pediatric MS
Monday, 18 Dec 2017 09:00am EST 

Dec 18 (Reuters) - Novartis Ag ::NOVARTIS MULTIPLE SCLEROSIS THERAPY FINGOLIMOD GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR PEDIATRIC MS.NOVARTIS- U.S. FDA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR FINGOLIMOD FOR TREATMENT OF CHILDREN, ADOLESCENTS 10 YEARS OR OLDER WITH RELAPSING MS.  Full Article

Ultragenyx Sells Priority Review Voucher For $130 Mln
Monday, 18 Dec 2017 08:30am EST 

Dec 18 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX SELLS PRIORITY REVIEW VOUCHER FOR $130 MILLION.ENTERED INTO A DEFINITIVE AGREEMENT TO SELL ITS RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER TO NOVARTIS.  Full Article

Novartis says Crizanlizumab Shown To Prolong Time To Patients' First Sickle Cell Pain Crisis
Monday, 11 Dec 2017 10:50am EST 

Dec 11 (Reuters) - Novartis Ag says::Its drug crizanlizumab was shown to prolong time to patients' first sickle cell pain crisis in a study..The drug approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN data..Discussions with health authorities continue; FDA filing anticipated by end of 2018 pending outcome of ongoing healthy volunteer bridging study..  Full Article

Novartis Division Sandoz Says New Phase I Data Showing Proposed Biosimilar Pegfilgrastim Matches Reference Medicine‍​
Friday, 8 Dec 2017 01:43am EST 

Dec 8 (Reuters) - Novartis ::DIVISION SANDOZ SAYS NEW PHASE I DATA SHOWING PROPOSED BIOSIMILAR PEGFILGRASTIM MATCHES REFERENCE MEDICINE‍​.  Full Article

Photo

Novartis's Kymriah wins speedy reviews in U.S., Europe

ZURICH Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment.